Tumor‐Associated Myeloid Cells Selective Delivery of a Therapeutic Tumor Nano‐Vaccine for Overcoming Immune Barriers for Effective and Long‐Term Cancer Immunotherapy
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202401416 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Chufan Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Biomedical Engineering of Fujian Province University/Research Center of Biomedical Engineering of Xiamen, Department of Biomaterial…. Hauptthemen laut MEDLINE: Immunotherapy, Cancer Vaccines. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fujian Provincial Science and Technology Department Guiding Project, Chongqing Talents Program.
Abstract (Originalsprache)
Therapeutic cancer vaccines have the potential to induce regression of established tumors, eradicate microscopic residual lesions, and prevent metastasis and recurrence, but their efficacy is limited by the low antigenicity of soluble antigens and the immunosuppressive tumor‐associated macrophages (TAMs) that promote tumor growth. In this study, a novel strategy is reported for overcoming these defenses: a dual‐targeting nano‐vaccine (NV) based on hepatitis B core antigen (HBcAg) derived virus‐like particles (VLPs), N‐M2T‐gp100 HBc NV, equipped with both SIGNR + dendritic cells (DCs)/TAMs‐targeting ability and high‐density display of tumor‐associated antigen (TAA). N‐M2T‐gp100 HBc NVs‐based immunotherapy has demonstrated an optimal interaction between tumor‐associated antigens (TAAs) and the immune composition of the tumor microenvironment. In a melanoma model, N‐M2T‐gp100 HBc VLPs significantly reducing in situ and abscopal tumor growth, and provide long‐term immune protection. This remarkable anti‐tumor effect is achieved by efficiently boosting of T cells and repolarizing of M2‐like TAMs. This work opens exciting avenues for the development of personalized tumor vaccines targeting not just melanoma but potentially a broad range of cancer types based on functionalized VLPs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Biomedical Engineering of Fujian Province University/Research Center of Biomedical Engineering of Xiamen, Department of Biomaterials, College of Materials, Xiamen University, Xiamen, 361005, P. R. Chin…
- School of Pharmaceutical Sciences, Xiamen University, Xiamen, 361102, P. R. China.
- School of Medicine, Xiamen University, Xiamen, 361102, P. R. China.
- Department of Pharmacology, College of Pharmacy, Army Medical University (Third Military Medical University), Chongqing, 400038, P.R. China.
- State Key Lab of Physical Chemistry of Solid Surfaces, Xiamen University, Xiamen, 361005, P. R. China.
ORCID-Profile: Lei Ren
Förderung
- National Natural Science Foundation of China
- Fujian Provincial Science and Technology Department Guiding Project
- Chongqing Talents Program
- Science and Technology Research Program of Chongqing Municipal Education Commission
- Special Basic Science and Cutting-edge Research Project of Chongqing
Zitieren
APA
Wang, C., Zhao, J., Duan, Y., Lin, L., Zhang, Q., Zheng, H., Shan, W., Wang, X., & Ren, L. (2024). Tumor‐Associated Myeloid Cells Selective Delivery of a Therapeutic Tumor Nano‐Vaccine for Overcoming Immune Barriers for Effective and Long‐Term Cancer Immunotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202401416
Vancouver
Wang C, Zhao J, Duan Y, Lin L, Zhang Q, Zheng H, et al. Tumor‐Associated Myeloid Cells Selective Delivery of a Therapeutic Tumor Nano‐Vaccine for Overcoming Immune Barriers for Effective and Long‐Term Cancer Immunotherapy. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202401416
BibTeX
@article{Wang2024,
author = {Wang, Chufan and Zhao, Jinglian and Duan, Yufei and Lin, Liping and Zhang, Qiang and Zheng, Haiping and Shan, Wenjun and Wang, Xiumin and Ren, Lei},
title = {Tumor‐Associated Myeloid Cells Selective Delivery of a Therapeutic Tumor Nano‐Vaccine for Overcoming Immune Barriers for Effective and Long‐Term Cancer Immunotherapy},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202401416}
}
EUVIMED